|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001792,
umls-concept:C0006684,
umls-concept:C0012798,
umls-concept:C0030705,
umls-concept:C0035171,
umls-concept:C0205195,
umls-concept:C0857121,
umls-concept:C1098320,
umls-concept:C1708476,
umls-concept:C2603343,
umls-concept:C2699007
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2009-3-5
|
|
pubmed:abstractText |
The COLM study is an investigator-initiated trial comparing the combination therapy using an angiotensin II receptor blocker (ARB), olmesartan, and a calcium channel blocker (CCB) with that using an ARB and a diuretic in high-risk elderly hypertensive patients. Here we describe the rationale and study design. Olmesartan was administered concomitantly with a long-acting dihydropyridine CCB (ARB/CCB group) or with a low-dose diuretic (ARB/diuretic group) to elderly hypertensive patients with a history of or risk factors for cardiovascular disease. Cardiovascular morbidity and mortality as a primary end point were compared between the two groups, with the target blood pressure (BP) being <140 mm Hg for systolic BP and <90 mm Hg for diastolic BP. Safety and tolerability will also be investigated. A total of more than 4000 patients were recruited and will be followed up for at least 3 years.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1348-4214
|
|
pubmed:author |
pubmed-author:COLM study investigators,
pubmed-author:HigakiJitsuoJ,
pubmed-author:HoriuchiMasatsuguM,
pubmed-author:ImaizumiTsutomuT,
pubmed-author:ItoSadayoshiS,
pubmed-author:KatayamaShigehiroS,
pubmed-author:MatsuokaHiroakiH,
pubmed-author:OgiharaToshioT,
pubmed-author:RakugiHiromiH,
pubmed-author:SaitoIkuoI,
pubmed-author:SarutaTakaoT,
pubmed-author:ShimadaKazuyukiK,
pubmed-author:ShimamotoKazuakiK,
pubmed-author:TakishitaShuichiS
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
32
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
163-7
|
|
pubmed:dateRevised |
2009-12-10
|
|
pubmed:meshHeading |
pubmed-meshheading:19262477-Aged,
pubmed-meshheading:19262477-Aged, 80 and over,
pubmed-meshheading:19262477-Angiotensin II Type 1 Receptor Blockers,
pubmed-meshheading:19262477-Antihypertensive Agents,
pubmed-meshheading:19262477-Calcium Channel Blockers,
pubmed-meshheading:19262477-Dihydropyridines,
pubmed-meshheading:19262477-Diuretics,
pubmed-meshheading:19262477-Double-Blind Method,
pubmed-meshheading:19262477-Drug Therapy, Combination,
pubmed-meshheading:19262477-Endpoint Determination,
pubmed-meshheading:19262477-Female,
pubmed-meshheading:19262477-Humans,
pubmed-meshheading:19262477-Hypertension,
pubmed-meshheading:19262477-Imidazoles,
pubmed-meshheading:19262477-Japan,
pubmed-meshheading:19262477-Male,
pubmed-meshheading:19262477-Prospective Studies,
pubmed-meshheading:19262477-Risk,
pubmed-meshheading:19262477-Tetrazoles
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Rationale, study design and implementation of the COLM study: the combination of OLMesartan and calcium channel blocker or diuretic in high-risk elderly hypertensive patients.
|
|
pubmed:affiliation |
Osaka University Graduate School of Medicine, Osaka, Japan.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
